

IN THE CLAIMS

Please add new claims 12 and 13.

12. A method for modulating a process selectively mediated by one or more Retinoid X Receptors, said method comprising causing said process to be conducted in the presence of at least one compound which selectively activates a Retinoid X Receptor in preference to a Retinoic Acid Receptor.

13. A method for treating a mammalian subject requiring Retinoid X Receptor therapy comprising administering to such subject a pharmaceutically effective amount of one or more compounds which selectively activate a Retinoid X Receptor in preference to a Retinoic Acid Receptor.

REMARKS

New claims 12 and 13 have been added to the application. These claims are directed to the disclosed methods utilizing compounds which selectively activate a Retinoid X Receptor (RXR) in preference to a Retinoic Acid Receptor (RAR). Support for these claims is found generally throughout the specification. For example, at pages 65-71 of the specification, compounds including 3-methyl-TTNCB and 3-methyl-TTNEB, among others are disclosed which preferentially activate Retinoid X Receptors versus Retinoic Acid Receptors. Additionally, pages 75-76 of the specification disclose compounds that readily activate RXRs in preference to RARs as evaluated by the co-

20250906 1021297

Sub 41